<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196868</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/44</org_study_id>
    <nct_id>NCT04196868</nct_id>
  </id_info>
  <brief_title>Methotrexate and Metformin in Rheumatoid Arthritis Patients</brief_title>
  <acronym>METorMET²</acronym>
  <official_title>Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite
      its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach
      RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and
      anti-inflammatory properties make it a good candidate for the treatment of inflammatory
      diseases such as rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methotrexate is usually the first-line disease modifying antirheumatic drugs (DMARD) for the
      treatment of RA. The main goal of its treatment is to reach disease remission but, despite
      its good efficacy, 1/3 of patients failed to achieve it. This could lead to the introduction
      of a biologic therapy which is more expensive and exposes the patient to a greater infection
      risk. Neutrophils through expulsion of neutrophil extracellular traps (NETs), were found to
      be important in RA pathogenesis (source of anti-citrullinated protein antibodies, activation
      of fibroblast-like synoviocytes…). The formation of NETs is reactive oxygen species (ROS)
      dependent, while metformin can selectivity inhibit mitochondrial respiratory chain complex I
      and decrease NADPH oxidase activity, thus leading to a decrease in ROS production.

      Metformin is the first-line therapy for type 2 diabetes. Recently, a study presented its
      potential impact in the treatment of systemic lupus erythematosus according to its metabolic
      properties and the inhibition of NETosis.

      The aim of this study is to compare the efficacy of Methotrexate/Metformin vs. Methotrexate
      alone on the decrease of RA activity in MTX-naive patients, after 6 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>placebo-controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of level of RA activity according to Disease Activity score on 28 joints (DAS28)</measure>
    <time_frame>At baseline (Day 0) and 6 months after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who reach remission</measure>
    <time_frame>At 6 months, 12 months and 24 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with low disease activity (DAS &lt; 3,2)</measure>
    <time_frame>At 6 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients for which a biologic treatment is introduced</measure>
    <time_frame>At 6 months, 12 months and 24 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dosage of Methotrexate in the two groups of randomization</measure>
    <time_frame>At 6 months, 12 months and 24 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who present a serious adverse event within the two groups</measure>
    <time_frame>At 6 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of functional assessment according to Health Assessment Questionnaire (HAQ) within the two groups</measure>
    <time_frame>At baseline (Day 0), 1 month, 3 months, 6 months, 12 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of weight in kilograms in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of waist circumference in centimeters in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of fasting glycemia in g/l in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of hemoglobin A1c level (HbA1c) in percentage in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of cholesterol levels and triglycerides levels in g/l in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of insulinemia in µUI/ml in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of bilirubin in mg/l in each randomization group</measure>
    <time_frame>At baseline (Day 0), 6 months and 24 months after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin treatment</intervention_name>
    <description>1500 mg once a day, per os, during six months</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>per os, during six months</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate treatment</intervention_name>
    <description>per os</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18 years old,

          -  Patient affected by RA according to American College of Rheumatology (ACR) 2010
             criteria

          -  DAS28 &gt; 3.2

          -  Methotrexate naïve patients, or without any methotrexate intake for more than six
             months.

          -  Men who accept to take active contraception during the study and during six months
             after the end of the Methotrexate treatment. Partner of patient will be informed of
             teratogenicity of MTX and will be advised to be on effective contraceptives for all
             the study duration.

        OR

          -  Women with a negative test of β-human chorionic gonadotropin (HCG) who accept to take
             active contraception during the study and during six months after the end of the
             Methotrexate treatment

          -  Patients without any Metformin previous therapy.

          -  Being affiliated to a health insurance system

          -  Having signed an informed consent form (later than the day of inclusion and before any
             examination required by the research)

        Exclusion Criteria:

          -  Patient who present contraindications to treatment with Methotrexate or Metformin

          -  Patient with type 1 or type 2 diabetes

          -  Patient with daily corticosteroid treatment at a dosage ≥ 15 mg/day within four weeks
             before the inclusion

          -  History of allergy or intolerance to biguanide

          -  Presence of anemia (hemoglobin &lt; 80 g/l), neutropenia (neutrophils count &lt; 1500 mm3),
             lymphopenia (lymphocytes count &lt; 750 mm3), thrombopenia (platelets &lt; 100 000/mm3) or
             bone marrow hypoplasia.

          -  Renal insufficiency with clearance &lt; 60 ml/mn

          -  Decompensated heart failure

          -  Coronary insufficiency

          -  Severe respiratory insufficiency

          -  Hepatic insufficiency, or bilirubin level upper than 5mg/dl (85,5 µmol/l), or
             aspartate transaminase (ASAT) / alanine aminotransferase (ALAT) more than twice the
             standard level.

          -  Acute or chronic infection, such as tuberculosis or HIV

          -  Critical ischemia of the lower limbs

          -  Recent stroke

          -  Patient with pleural effusion, or ascites

          -  Patient with stomatitis, mouth ulcers, or active gastrointestinal ulcer.

          -  Patient with alcohol intoxication

          -  B12 Vitamin deficiency

          -  Patient performing or planning to perform a long-fasting period

          -  Pregnant or breastfeeding women

          -  Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty
             by a judicial or administrative decision, minors, persons of legal age who are the
             object of a legal protection measure or unable to express their consent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe RICHEZ, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU - Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine BENARD, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe RICHEZ, Prof</last_name>
    <phone>(0)556795556</phone>
    <phone_ext>+33</phone_ext>
    <email>christophe.richez@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas BARNETCHE, PhD</last_name>
    <phone>(0)557820493</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.barnetche@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de rhumatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <email>christophe.richez@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas BARNETCHE, PhD</last_name>
      <email>thomas.barnetche@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - service de rhumatologie</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain SARAUX, Prof</last_name>
      <email>alain.saraux@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Alain SARAUX, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Cahors - service de rhumatologie</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Slim LASSOUED, MD</last_name>
      <email>lassoued3@ch-cahors.fr</email>
    </contact>
    <investigator>
      <last_name>Slim LASSOUED, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Mans - service de rhumatologie</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle DERNIS, MD</last_name>
      <email>edernis@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle DERNIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Libourne - service de rhumatologie</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphanie DUBLANC, MD</last_name>
      <email>stephanie.dublanc@ch-libourne.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie DUBLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - service de rhumatologie</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale VERGNES-SALLES, Prof</last_name>
      <email>pascale.vergne-salle@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale VERGNES-SALLES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - service de rhumatologie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques MOREL, Prof</last_name>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques MOREL, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans la Source - service de rhumatologie</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carine SALLIOT, MD</last_name>
      <email>carine.salliot@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Carine SALLIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - service de rhumatolgie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
      <email>ruyssen-witrand.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>methotrexate</keyword>
  <keyword>metformin</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

